Information Provided By: 
Fly News Breaks for February 22, 2018
GSK, GILD
Feb 22, 2018 | 07:06 EDT
Leerink analyst Seamus Fernandez notes he has recently completed a MEDACorp survey of U.S. HIV treatment specialists and has found "impressively positive" sentiment about Gilead's (GILD) Biktarvy which seems likely to put sustained pressure on GlaxoSmithKline's (GSK) leading integrase inhibitor Tivicay, as well as cannibalizing Gilead's other combination and component products.
News For GILD;GSK From the Last 2 Days
GSK
Apr 23, 2024 | 08:34 EDT
GILD
Apr 22, 2024 | 07:19 EDT
Cantor Fitzgerald lowered the firm's price target on Gilead to $75 from $78 and keeps a Neutral rating on the shares. The firm, which made slight adjustments to all of its large-cap biotechnology models ahead of Q1 earnings season for the group, lowered its target for Gilead given slower expected HIV growth. The "usual seasonal headwinds that typically make this one of the weaker quarters for the industry," the analyst added in the preview note.
